Contact
searchSearch
HMP Global

Advertisement

ADVERTISEMENT

Video

Endothelialization of Amplatzer PFO Occluder Device 12 Months Post Implantation

Yasuhiro Tanabe, MD, PhD
Yoshihiro J. Akashi, MD, PhD
Tomomi Suzuki, MD, PhD
Shingo Kuwata, MD, PhD
01/31/2022

Introduction

Video supplement to “Endothelialization of Amplatzer PFO Occluder Device 12 Months After Implantation: First-in-Human Angioscopic Assessment,” by Tanabe, et al. (February 2022 Clinical Images).

The current guidelines recommend at least 6-month antithrombotic and antibiotic prophylaxis following atrial septal occluding device placement using the phrase “until endothelialization.” However, neo-endothelialization has not been assessed in vivo in humans. The following angioscope series demonstrates the first evaluation of PFO occluder device neo-endothelialization in vivo.

Read the article HERE

Supplemental Video


Advertisement

Advertisement

Advertisement

News

elective surgery post MI
Researchers Identify 'Sweet Spot' for Safe Surgery After Heart Attack
11/04/2024
"The data physicians are using for patient care decisions today is outdated. Given the advances in care and the ever-changing mix of patients, clinicians need the latest information," said Laurent Glance, MD. The recommendation was based on a...
"The data physicians are using for patient care decisions today is outdated. Given the advances in care and the ever-changing mix of patients, clinicians need the latest information," said Laurent Glance, MD. The recommendation was based on a...
"The data physicians are using...
11/04/2024
Cath Lab Digest
reimbursement
Elucid Announces CCTA Reimbursement to Be Doubled With CMS Rule
11/04/2024
Those decisions further recognize the importance of new technologies like Elucid’s PlaqueIQTM that can help non-invasively quantify and classify coronary artery plaque and its components such as lipid-rich necrotic core (LRNC), giving...
Those decisions further recognize the importance of new technologies like Elucid’s PlaqueIQTM that can help non-invasively quantify and classify coronary artery plaque and its components such as lipid-rich necrotic core (LRNC), giving...
Those decisions further...
11/04/2024
Cath Lab Digest
Pulmonary Embolism
Akura Medical Secures FDA Approval for US Pivotal Trial in Pulmonary Embolism
11/04/2024
QUADRA-PE study will evaluate the safety and effectiveness of the Katana™ Thrombectomy System LOS GATOS, Calif., Nov. 4, 2024 /PRNewswire/ -- Akura Medical, a Shifamed portfolio company focused on reshaping the...
QUADRA-PE study will evaluate the safety and effectiveness of the Katana™ Thrombectomy System LOS GATOS, Calif., Nov. 4, 2024 /PRNewswire/ -- Akura Medical, a Shifamed portfolio company focused on reshaping the...
QUADRA-PE study will evaluate...
11/04/2024
Vascular Disease Management
IVL + Laser Atherectomy
Philips Enrolls First Patient in U.S. Clinical Trial for Innovative Integrated Single Device to Treat PAD
11/04/2024
Royal Philips announced enrollment of the first patient in the U.S. THOR IDE clinical trial, which will study an innovative combined laser atherectomy and intravascular lithotripsy catheter developed by Philips that integrates two critical...
Royal Philips announced enrollment of the first patient in the U.S. THOR IDE clinical trial, which will study an innovative combined laser atherectomy and intravascular lithotripsy catheter developed by Philips that integrates two critical...
Royal Philips announced...
11/04/2024
Cath Lab Digest
Renal Denervation
Recor Medical Announces CMS Grant of Transitional Pass-Through (TPT) Payment for Recor’s Paradise Ultrasound Renal Denervation System for the Treatment of Uncontrolled Hypertension
11/04/2024
The Paradise uRDN system is an ultrasound-based RDN technology designed to lower blood pressure by denervating the sympathetic nerves surrounding the renal arteries, reducing the overactivity that can lead to hypertension.
The Paradise uRDN system is an ultrasound-based RDN technology designed to lower blood pressure by denervating the sympathetic nerves surrounding the renal arteries, reducing the overactivity that can lead to hypertension.
The Paradise uRDN system is an...
11/04/2024
Cath Lab Digest
Bioresorbable Scaffolds
FDA Grants R3 Vascular IDE Approval for ELITE-BTK Pivotal Trial of Its Magnitude Drug-Eluting Next-Generation Bioresorbable Scaffold for BTK PAD
11/04/2024
Eric A. Secemsky, MD, MSc, lead investigator for the ELITE-BTK pivotal trial, said, “This is a much-anticipated trial given the advancements and advantages of this next-generation technology which has the potential to transform the field of...
Eric A. Secemsky, MD, MSc, lead investigator for the ELITE-BTK pivotal trial, said, “This is a much-anticipated trial given the advancements and advantages of this next-generation technology which has the potential to transform the field of...
Eric A. Secemsky, MD, MSc, lead...
11/04/2024
Cath Lab Digest
reimbursement
HeartFlow Announces New Decision from Centers for Medicare & Medicaid Services Boosting CCTA Reimbursement and Access
11/04/2024
From one single test, CCTA provides a comprehensive view of a patient’s CAD and guides treatment planning when combined with HeartFlow fractional flow reserve computed tomography (FFRCT) and Plaque Analysis.
From one single test, CCTA provides a comprehensive view of a patient’s CAD and guides treatment planning when combined with HeartFlow fractional flow reserve computed tomography (FFRCT) and Plaque Analysis.
From one single test, CCTA...
11/04/2024
Cath Lab Digest
renal denervation
CMS Grants Transitional Pass-Through Payment for Medtronic Symplicity Spyral Renal Denervation Catheter
11/04/2024
CMS has granted transitional pass-through (TPT) payment for the Medtronic Symplicity Spyral™ renal denervation catheter, used in the Symplicity™ blood pressure procedure, under the Medicare Hospital Outpatient Prospective Payment System. TPT...
CMS has granted transitional pass-through (TPT) payment for the Medtronic Symplicity Spyral™ renal denervation catheter, used in the Symplicity™ blood pressure procedure, under the Medicare Hospital Outpatient Prospective Payment System. TPT...
CMS has granted transitional...
11/04/2024
Cath Lab Digest
DCB
SIRONA Trial @TCT – First Head-to-Head Comparison of Sirolimus Versus Paclitaxel DCBs in the Treatment of PAD: Sirolimus-Coated Balloons Yield Similar Results to Paclitaxel-Coated Balloons in the Femoropopliteal Artery
10/30/2024
Data from the prospective, multicenter, investigator-initiated SIRONA randomized clinical trial demonstrated MagicTouch™️ sirolimus-coated balloons to be noninferior compared to paclitaxel-coated balloons with regards to the primary safety...
Data from the prospective, multicenter, investigator-initiated SIRONA randomized clinical trial demonstrated MagicTouch™️ sirolimus-coated balloons to be noninferior compared to paclitaxel-coated balloons with regards to the primary safety...
Data from the prospective,...
10/30/2024
Cath Lab Digest
acute mI
CLEAR SYNERGY (OASIS 9) Trial @TCT: Routine Colchicine Administration After Acute Myocardial Infarction Does Not Improve Outcomes
10/30/2024
Colchicine is an oral medication that reduces inflammation and smaller studies have indicated potential benefits for cardiovascular patients.
Colchicine is an oral medication that reduces inflammation and smaller studies have indicated potential benefits for cardiovascular patients.
Colchicine is an oral medication...
10/30/2024
Cath Lab Digest

Advertisement

Advertisement

elective surgery post MI
Researchers Identify 'Sweet Spot' for Safe Surgery After Heart Attack
11/04/2024
"The data physicians are using for patient care decisions today is outdated. Given the advances in care and the ever-changing mix of patients, clinicians need the latest information," said Laurent Glance, MD. The recommendation was based on a...
"The data physicians are using for patient care decisions today is outdated. Given the advances in care and the ever-changing mix of patients, clinicians need the latest information," said Laurent Glance, MD. The recommendation was based on a...
"The data physicians are using...
11/04/2024
Cath Lab Digest
reimbursement
Elucid Announces CCTA Reimbursement to Be Doubled With CMS Rule
11/04/2024
Those decisions further recognize the importance of new technologies like Elucid’s PlaqueIQTM that can help non-invasively quantify and classify coronary artery plaque and its components such as lipid-rich necrotic core (LRNC), giving...
Those decisions further recognize the importance of new technologies like Elucid’s PlaqueIQTM that can help non-invasively quantify and classify coronary artery plaque and its components such as lipid-rich necrotic core (LRNC), giving...
Those decisions further...
11/04/2024
Cath Lab Digest
Pulmonary Embolism
Akura Medical Secures FDA Approval for US Pivotal Trial in Pulmonary Embolism
11/04/2024
QUADRA-PE study will evaluate the safety and effectiveness of the Katana™ Thrombectomy System LOS GATOS, Calif., Nov. 4, 2024 /PRNewswire/ -- Akura Medical, a Shifamed portfolio company focused on reshaping the...
QUADRA-PE study will evaluate the safety and effectiveness of the Katana™ Thrombectomy System LOS GATOS, Calif., Nov. 4, 2024 /PRNewswire/ -- Akura Medical, a Shifamed portfolio company focused on reshaping the...
QUADRA-PE study will evaluate...
11/04/2024
Vascular Disease Management
IVL + Laser Atherectomy
Philips Enrolls First Patient in U.S. Clinical Trial for Innovative Integrated Single Device to Treat PAD
11/04/2024
Royal Philips announced enrollment of the first patient in the U.S. THOR IDE clinical trial, which will study an innovative combined laser atherectomy and intravascular lithotripsy catheter developed by Philips that integrates two critical...
Royal Philips announced enrollment of the first patient in the U.S. THOR IDE clinical trial, which will study an innovative combined laser atherectomy and intravascular lithotripsy catheter developed by Philips that integrates two critical...
Royal Philips announced...
11/04/2024
Cath Lab Digest
Renal Denervation
Recor Medical Announces CMS Grant of Transitional Pass-Through (TPT) Payment for Recor’s Paradise Ultrasound Renal Denervation System for the Treatment of Uncontrolled Hypertension
11/04/2024
The Paradise uRDN system is an ultrasound-based RDN technology designed to lower blood pressure by denervating the sympathetic nerves surrounding the renal arteries, reducing the overactivity that can lead to hypertension.
The Paradise uRDN system is an ultrasound-based RDN technology designed to lower blood pressure by denervating the sympathetic nerves surrounding the renal arteries, reducing the overactivity that can lead to hypertension.
The Paradise uRDN system is an...
11/04/2024
Cath Lab Digest
Bioresorbable Scaffolds
FDA Grants R3 Vascular IDE Approval for ELITE-BTK Pivotal Trial of Its Magnitude Drug-Eluting Next-Generation Bioresorbable Scaffold for BTK PAD
11/04/2024
Eric A. Secemsky, MD, MSc, lead investigator for the ELITE-BTK pivotal trial, said, “This is a much-anticipated trial given the advancements and advantages of this next-generation technology which has the potential to transform the field of...
Eric A. Secemsky, MD, MSc, lead investigator for the ELITE-BTK pivotal trial, said, “This is a much-anticipated trial given the advancements and advantages of this next-generation technology which has the potential to transform the field of...
Eric A. Secemsky, MD, MSc, lead...
11/04/2024
Cath Lab Digest
reimbursement
HeartFlow Announces New Decision from Centers for Medicare & Medicaid Services Boosting CCTA Reimbursement and Access
11/04/2024
From one single test, CCTA provides a comprehensive view of a patient’s CAD and guides treatment planning when combined with HeartFlow fractional flow reserve computed tomography (FFRCT) and Plaque Analysis.
From one single test, CCTA provides a comprehensive view of a patient’s CAD and guides treatment planning when combined with HeartFlow fractional flow reserve computed tomography (FFRCT) and Plaque Analysis.
From one single test, CCTA...
11/04/2024
Cath Lab Digest
renal denervation
CMS Grants Transitional Pass-Through Payment for Medtronic Symplicity Spyral Renal Denervation Catheter
11/04/2024
CMS has granted transitional pass-through (TPT) payment for the Medtronic Symplicity Spyral™ renal denervation catheter, used in the Symplicity™ blood pressure procedure, under the Medicare Hospital Outpatient Prospective Payment System. TPT...
CMS has granted transitional pass-through (TPT) payment for the Medtronic Symplicity Spyral™ renal denervation catheter, used in the Symplicity™ blood pressure procedure, under the Medicare Hospital Outpatient Prospective Payment System. TPT...
CMS has granted transitional...
11/04/2024
Cath Lab Digest
TAVR
TAVR UNLOAD @TCT: Transcatheter Aortic Valve Replacement in Patients with Systolic Heart Failure and Moderate Aortic Stenosis Shows Limited Benefits
10/30/2024
Findings from the TAVR UNLOAD study found limited benefits of transcatheter aortic valve replacement (TAVR) in the treatment of heart failure (HF) with reduced ejection fraction (HFrEF) and moderate aortic stenosis (AS).
Findings from the TAVR UNLOAD study found limited benefits of transcatheter aortic valve replacement (TAVR) in the treatment of heart failure (HF) with reduced ejection fraction (HFrEF) and moderate aortic stenosis (AS).
Findings from the TAVR UNLOAD...
10/30/2024
Cath Lab Digest
DCB
SIRONA Trial @TCT – First Head-to-Head Comparison of Sirolimus Versus Paclitaxel DCBs in the Treatment of PAD: Sirolimus-Coated Balloons Yield Similar Results to Paclitaxel-Coated Balloons in the Femoropopliteal Artery
10/30/2024
Data from the prospective, multicenter, investigator-initiated SIRONA randomized clinical trial demonstrated MagicTouch™️ sirolimus-coated balloons to be noninferior compared to paclitaxel-coated balloons with regards to the primary safety...
Data from the prospective, multicenter, investigator-initiated SIRONA randomized clinical trial demonstrated MagicTouch™️ sirolimus-coated balloons to be noninferior compared to paclitaxel-coated balloons with regards to the primary safety...
Data from the prospective,...
10/30/2024
Cath Lab Digest

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use

Advertisement

Advertisement